Dr. Charles Mulamba, recipient of European Vaccine Initiative PhD fellowship, successfully graduated last week at Nelson Mandela African Institution of Science and Technology, Tanzania.

Working with the Inno4Vac consortium coordinated by European Vaccine Initiative, Naobios will leverage Nuvonis’s Vero Cell Bank to...

This EVI-sponsored clinical trial of the full-length MSP1/GLA-SE vaccine candidate, reflects our commitment to innovation in malaria vaccine development.

New EVI-led project aims to boost malaria control with innovative vaccine technology through international partnership and support by the Global Health Innovative Technology (GHIT) Fund with an investment of approximately JPY 800 million. The core aim of SEmalvac6 is to advance the biomanufacture and preclinical development of the blood-stage malaria vaccine candidate SE36/cVLP.

The SUNSHINE trial has now proceeded to the start of vaccination of participants living in Shigella endemic setting at the Centre for Infectious Disease Research in Zambia (CIDRZ).

A delegation from BioNTech visited the European Vaccine Initiative (EVI) to engage in a dialogue focused on strengthening global capacity building efforts and supporting scientific training for fellows hosted by both organisations. 

An interactive online workshop titled “Strategies for using Malaria vaccines to prevent Malaria in pregnancy” was held on June 3rd,...

The courses were led by the EVI and designed to strengthen capacity in vaccine research and development (R&D), with a particular focus on supporting professionals from low- and middle-income countries (LMICs).

World Malaria Day is observed every year on 25 April to recognise global efforts to control malaria.